Galapagos ( (GLPG) ) has shared an update.
Galapagos NV has published its 2024 annual report and announced its Annual Shareholders’ Meeting scheduled for April 29, 2025, in Mechelen, Belgium. The meeting will address key agenda items, including the appointment of Mr. Oleg Nodelman as Non-Executive Non-Independent Director and the confirmation of the statutory auditor for sustainability reporting. Notably, the proposed separation of Galapagos into two entities is not on the agenda, with an Extraordinary Shareholders’ Meeting expected later in 2025. This announcement highlights Galapagos’ ongoing commitment to transparency and strategic planning, potentially impacting its market positioning and stakeholder relations.
More about Galapagos
Galapagos is a biotechnology company operating in Europe and the U.S., focusing on transforming patient outcomes through innovative science and technology. The company addresses high unmet medical needs by developing a deep pipeline of best-in-class medicines, leveraging a decentralized cell therapy manufacturing platform. Galapagos aims to challenge the status quo in healthcare and deliver impactful results for patients, employees, and shareholders.
YTD Price Performance: -8.60%
Average Trading Volume: 260,130
Technical Sentiment Signal: Buy
Current Market Cap: $1.68B
See more data about GLPG stock on TipRanks’ Stock Analysis page.